Effects of Multistrain Probiotic Supplementation on Glycemic and Inflammatory Indices in Patients with Nonalcoholic Fatty Liver Disease: A Double-Blind Randomized Clinical Trial
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Nonalcoholic fatty liver disease (NAFLD) is a condition defined by exceeding triglycerides accumulation in the liver. The condition can develop into fibrosis, cirrhosis, and hepatocellular carcinoma. Considering the ever-increasing prevalence of NAFLD, the aim of the present study was to investigate the effects of probiotic supplementation on glycemic and inflammatory indices in patients with NAFLD. METHODS: This randomized clinical trial was conducted on 42 patients with NAFLD who had been referred to a gastroenterology clinic. Subjects in the intervention and control groups consumed 2 capsules/day probiotic or placebo, respectively, for 8 weeks. Fasting blood sugar (FBS), insulin, insulin resistance, tumor necrosis factor alpha (TNF-α), and interleukin 6 (IL-6) were measured at baseline and at the end of the study. RESULTS: Means of FBS, insulin, insulin resistance, and IL-6 were significantly different between groups after intervention (p < 0.05), whereas TNF-α was not significantly modified (p > 0.05). In the probiotic group, insulin, insulin resistance, TNF-α, and IL-6 decreased significantly at the end of the study compared to the beginning of study. CONCLUSION: Considering the effects of probiotic supplementation on the reduction of glycemic and inflammatory indices in patients with NAFLD, consumption of probiotics is recommended as a complementary therapy in these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cani, P. D., Possemiers, S., Van de Wiele, T., Guiot, Y., Everard, A., Rottier, O., Geurts, L., Naslain, D., Neyrinck, A., Lambert, D. M., et al. (2009) · Gut · doi:10.1136/gut.2008.165886 · Cited by 2,518 · cited 1×
“The intestinal microbiota of diabetic mice can be altered with prebiotic supplementation to increase Bifidobacterium, Lactobacillus, and Clostridium coccoides, thereby producing lower plasma LPS and cytokine levels and decreased hepatic expression of inflammatory and oxidative stress markers [26].”
BackgroundLactobacillus rhamnosus GG protects against non-alcoholic fatty liver disease in mice
Ritze, Y., Bárdos, G., Claus, A., Ehrmann, V., Bergheim, I., Schwiertz, A., & Bischoff, S. C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0080169 · Cited by 292 · cited 1×
“[21] have recently found that probiotic may reduce insulin, insulin resistance, TNF-a, and IL-1b levels in rats with NAFLD.”
Background
Cited by
Targeting the gut-liver axis in liver disease
Wiest, R., Albillos, A., Trauner, M., Bajaj, J. S., & Jalan, R. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.007 · Cited by 419
Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
Rong, L., Zou, J., Ran, W., Qi, X., Chen, Y., Cui, H., & Guo, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1087260 · Cited by 301
Koutnikova, H., Genser, B., Monteiro-Sepulveda, M., Faurie, J.-M., Rizkalla, S., Schrezenmeir, J., & Clément, K. (2019) · BMJ Open · doi:10.1136/bmjopen-2017-017995 · Cited by 299
Sun, L., Ma, L., Ma, Y., Zhang, F., Zhao, C., & Nie, Y. (2018) · Protein & Cell · doi:10.1007/s13238-018-0546-3 · Cited by 253
The effect of probiotics on inflammatory biomarkers: A meta-analysis of randomized clinical trials
Milajerdi, A., Mousavi, S. M., Sadeghi, A., Salari-Moghaddam, A., Parohan, M., Larijani, B., & Esmaillzadeh, A. (2020) · European Journal of Nutrition · doi:10.1007/s00394-019-01931-8 · Cited by 123
Metadata
- Authors
- Sepideh, A., Karim, P., Hossein, A., Leila, R., Hamdollah, M., Mohammad E, G., Mojtaba, S., Mohammad, S., Ghader, G., & Seyed Moayed, A.
- Venue
- Journal of the American College of Nutrition
- Publisher
- Informa UK Limited
- Published
- 2015-10-02
- Volume
- 35
- Issue
- 6
- Pages
- 500-505
- ISSN
- 0731-5724 (ISSN-L)
- 1541-1087
- OpenAlex
- W2241775397
- Cited by
- 132
- References
- 2
- FWCI
- 7.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.